Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Andecaliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
- 09 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2016.